Cardioembolic stroke is a dangerous subtype of ischemic stroke. Patients with this subtype need special treatments to prevent recurrent events that might be fatal. Thus, identifying underlying stroke ...

Here we demonstrate a difference-frequency ultrasound (dfUS) imaging method that is based on the interaction of two sound pulses that propagate non-collinearly and intersect in space and time. The ...

Looking for reliable MRI spine services in Solan? Learn how to choose the right center for MRI in Solan, MRI brain, fetal MRI ...

Magnetic resonance angiography – also called a magnetic resonance angiogram or MRA – is a type of MRI that looks specifically at the body’s blood vessels.

Abstract Herein we report a novel gadolinium-encapsulating iron oxide nanoparticle-based activatable NMR/MRI nanoprobe. In our design, Gd-DTPA is encapsulated within the poly (acrylic acid) (PAA) ...

We describe the rational design of a novel class of magnetic resonance imaging (MRI) contrast agents with engineered proteins (CAi.CD2, i = 1, 2,..., 9) chelated with gadolinium. The design of protein ...

MRI is the diagnostic modality of choice (9) . The migrated disc usually appears similar, although not identical to the cerebral spinal fluid signal intensity and exhibits rim enhancement on the post ...

MRI is a completely non-invasive technique in the absence of contrast agents like gadolinium (Gd), providing valuable evidence to assess WM damage and neurodegeneration in vivo. In addition, unlike ...

MRI detects missed cervical spine injuries in patients with negative CT results, prompting treatment changes, a meta-analysis reveals.

Among several invasive and noninvasive imaging modalities, magnetic resonance imaging (MRI) is emerging as a promising option. Advantages include its versatility, excellent soft tissue contrast for ...

The global MRI market will rise from USD 6.47 billion in 2025 to USD 9.76 billion by 2035, growing at a CAGR of 4.2%. By product type, closed MRI systems will dominate with a 68.5% share in 2025, ...

Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use ...